Exogenous human growth hormone reduces body fat in obese women.
The effects of biosynthetic methionyl human growth hormone (met-hGH) on body composition and endogenous secretion of insulin-like growth factor I (IGF-I) were studied in obese women ranging between 138 and 226% of ideal body weight. Following double-blind procedures, 12 subjects were assigned at random to either treatment with met-hGH (n = 6, 0.08 mg/kg desirable body weight) or placebo (n = 6, bacteriostatic water diluent). Treatments were delivered intramuscularly three times per week for a period of 27-28 days. Subjects were instructed to follow a weight-maintaining diet and their pre- and posttreatment kilocaloric intake was monitored for verification. The baseline peak serum GH response to L-dopa/arginine stimulation for the study population as a whole, was in the hyposecretory range (9.6 +/- 1.9 ng/ml), accompanied by a low level of circulating IGF-I (0.56 +/- 0.09 U/ml). Hydrodensitometry revealed that the met-hGH-treated subjects had a significant reduction in body fat, while an observed mean increase in fat-free mass (FFM) approached significance. The percent change in body fat was unrelated to pretreatment levels of body fat, total body weight, or initial endogenous GH status. Changes in circulating IGF-I were similar to those for FFM, with increases approaching significance. There were no significant changes in body composition or IGF-I in the placebo-treated subjects. No significant differences were observed in the self-reported dietary intake of kilocalories during the experimental period between the two groups. We conclude that exogenous GH reduces body fat in obese women in the apparent absence of significant kilocaloric restriction. The effect appears to be unrelated to endogenous GH secretion or body composition.
Skaggs
S R
SR
Department of Physiology, University of New Mexico, School of Medicine, Albuquergue.
Crist
D M
DM
D000273:Adipose Tissue; D000328:Adult; D001120:Arginine; D001823:Body Composition / Q000187:drug effects*; D002149:Energy Intake; D005260:Female; D013006:Growth Hormone / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D019382:Human Growth Hormone; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007980:Levodopa; D008875:Middle Aged; D009765:Obesity / Q000178:diet therapy / Q000503:physiopathology*
D019382:Human Growth Hormone; D007980:Levodopa; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D001120:Arginine